Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2017 Status changed from recruiting to discontinued.
- 05 Dec 2016 Status changed from not yet recruiting to recruiting.
- 15 Jun 2016 Planned initiation date changed from 1 Feb 2016 to 1 Jun 2016.